A £1.3m multicentre national programme of research has launched in the UK, evaluating how new diagnostic tests for Covid-19 perform in different healthcare settings.

Determining who has been infected with Covid-19 is key in responding to the pandemic, and brand-new diagnostic tests have cropped up across the life sciences industry. However, many of these tests have yet to be thoroughly evaluated in the settings where they’re likely to be used.

The Covid-19 National DiagnOstic Research and Evaluation Platform (CONDOR) – funded by the National Institute for Health Research, UK Research and Innovation, Asthma UK and the British Lung Foundation – will create a single national route for evaluating new diagnostic tests in hospitals and community healthcare settings.

The research team will work with the government and its advisors to identify which new commercially developed tests could be most valuable to the NHS. The effectiveness of the tests will then be evaluated in a number of different health and care settings, from emergency departments to care homes.

CONDOR will follow up with patients who test positive, administering an antibody test. Should they test positive for antibodies, they will then be monitored to find out whether they develop new infections, to assess whether people with antibodies are immune to reinfection and how long this immunity period might last.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.